[{"address1": "3027 Townsgate Road", "address2": "Suite 300", "city": "Westlake Village", "state": "CA", "zip": "91361", "country": "United States", "phone": "805 418 5006", "website": "https://www.arcutis.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.", "fullTimeEmployees": 296, "companyOfficers": [{"maxAge": 1, "name": "Mr. Todd Franklin Watanabe M.A.", "age": 55, "title": "President, CEO & Director", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 1007696, "exercisedValue": 0, "unexercisedValue": 415084}, {"maxAge": 1, "name": "Dr. Bhaskar  Chaudhuri Ph.D.", "age": 68, "title": "Co-Founder & Independent Director", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 60833, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Patrick E. Burnett M.D., Ph.D.", "age": 51, "title": "Senior VP & Chief Medical Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 722940, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. L. Todd Edwards", "age": 59, "title": "Senior VP & Chief Commercial Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 755641, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David J. Topper", "age": 65, "title": "Senior VP & Chief Financial Officer", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rajvir  Madan", "title": "Chief Digital & Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Latha  Vairavan", "title": "Vice President of Finance & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Courtney  Barton", "age": 40, "title": "VP and Chief Compliance Officer & Privacy Officer", "yearBorn": 1983, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Masaru  Matsuda Esq., J.D.", "age": 52, "title": "Senior VP, General Counsel & Corporate Secretary", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 626218, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amanda  Sheldon", "title": "Head of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 5, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 10.4, "open": 10.5, "dayLow": 10.3502, "dayHigh": 11.35, "regularMarketPreviousClose": 10.4, "regularMarketOpen": 10.5, "regularMarketDayLow": 10.3502, "regularMarketDayHigh": 11.35, "beta": 1.185, "forwardPE": -11.040815, "volume": 4257442, "regularMarketVolume": 4257442, "averageVolume": 2127859, "averageVolume10days": 2582950, "averageDailyVolume10Day": 2582950, "bid": 8.05, "ask": 13.4, "bidSize": 200, "askSize": 200, "marketCap": 1266426880, "fiftyTwoWeekLow": 1.76, "fiftyTwoWeekHigh": 13.17, "priceToSalesTrailing12Months": 9.130165, "fiftyDayAverage": 9.6697, "twoHundredDayAverage": 9.305375, "currency": "USD", "enterpriseValue": 1144039424, "profitMargins": -1.4096899, "floatShares": 85833480, "sharesOutstanding": 117045000, "sharesShort": 28064868, "sharesShortPriorMonth": 24863988, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.2401, "heldPercentInsiders": 0.02155, "heldPercentInstitutions": 1.11851, "shortRatio": 14.47, "shortPercentOfFloat": 0.29709998, "impliedSharesOutstanding": 117045000, "bookValue": 1.339, "priceToBook": 8.080657, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -195535008, "trailingEps": -1.67, "forwardEps": -0.98, "pegRatio": -0.79, "enterpriseToRevenue": 8.248, "enterpriseToEbitda": -6.377, "52WeekChange": 4.127962, "SandP52WeekChange": 0.35905516, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ARQT", "underlyingSymbol": "ARQT", "shortName": "Arcutis Biotherapeutics, Inc.", "longName": "Arcutis Biotherapeutics, Inc.", "firstTradeDateEpochUtc": 1580481000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "2fecbc50-3c9a-3138-8f51-5317e20e84cd", "messageBoardId": "finmb_549019944", "gmtOffSetMilliseconds": -18000000, "currentPrice": 10.82, "targetHighPrice": 29.0, "targetLowPrice": 12.0, "targetMeanPrice": 19.0, "targetMedianPrice": 19.0, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 330560992, "totalCashPerShare": 2.824, "ebitda": -179408000, "totalDebt": 208178000, "quickRatio": 2.266, "currentRatio": 2.457, "totalRevenue": 138708000, "debtToEquity": 132.901, "revenuePerShare": 1.228, "returnOnAssets": -0.3114, "returnOnEquity": -1.9230599, "freeCashflow": -96382624, "operatingCashflow": -167654000, "revenueGrowth": 0.174, "grossMargins": 0.89569, "ebitdaMargins": -1.29342, "operatingMargins": -0.87289, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-11"}]